Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Tumor-Agnostic 1

Conditions

Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

Carboplatin 62Paclitaxel 61Specimen Handling 37Cisplatin 37Taxes 35Magnetic Resonance Spectroscopy 31Bevacizumab 30Immunoglobulin G 23Disulfides 23Biopsy 22Cyclophosphamide 19aldesleukin 17Topotecan 16Brachytherapy 16Radiotherapy 15Gemcitabine 15veliparib 14Oxaliplatin 13Doxorubicin 13temsirolimus 12fludarabine 12Platinum 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 12olaparib 11liposomal doxorubicin 10cediranib 10Sirolimus 10Radiation 9Nivolumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Panitumumab × Gynecologic × Clear all
NCT05564377 2026-06-02

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT01158248 2010-07-09

Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
50 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡